---
title: "《盈警》北森控股亏损大减  上半年最多蚀 2,380 万人民币"
description: "北森控股发盈警，预计 6 月止六个月亏损介乎 1,460 万至 2,380 万人民币，相较上年同期亏损 9,900 万人民币，降幅介乎 76%-85%。主要由于以股份为基础付款减少；及收入预计增加 15.2%-20.5%，至 5.03 亿至 5.26 亿人民币。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/262266122.md"
published_at: "2025-10-22T14:00:12.000Z"
---

# 《盈警》北森控股亏损大减  上半年最多蚀 2,380 万人民币

> 北森控股发盈警，预计 6 月止六个月亏损介乎 1,460 万至 2,380 万人民币，相较上年同期亏损 9,900 万人民币，降幅介乎 76%-85%。主要由于以股份为基础付款减少；及收入预计增加 15.2%-20.5%，至 5.03 亿至 5.26 亿人民币。

北森控股 (09669.HK) 发盈警，预计 6 月止六个月亏损介乎 1,460 万至 2,380 万人民币，相较上年同期亏损 9,900 万人民币，降幅介乎 76%-85%。主要由於以股份为基础付款减少；及收入预计增加 15.2%-20.5%，至 5.03 亿至 5.26 亿人民币。

### Related Stocks

- [09669.HK - 北森控股](https://longbridge.com/zh-CN/quote/09669.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Hansoh Pharmaceutical Says Aumolertinib Mesylate Tablets Approved In EU As Monotherapy | Hansoh Pharmaceutical Group Company Ltd :AUMOLERTINIB MESYLATE TABLETS APPROVED IN EU AS MONOTHERAPY | [Link](https://longbridge.com/zh-CN/news/276401882.md) |
| Hansoh Pharmaceutical Group Company Limited Announces Approval in the European Union as Monotherapy | Hansoh Pharmaceutical Group Company Limited announced that Aumolertinib Mesylate Tablets, known as Ameile in China, rece | [Link](https://longbridge.com/zh-CN/news/276480305.md) |
| Hansoh Wins EU Approval for Key Lung Cancer Drug Aumolertinib | Hansoh Wins EU Approval for Key Lung Cancer Drug Aumolertinib | [Link](https://longbridge.com/zh-CN/news/276393466.md) |
| Berkshire Hathaway discloses investment in New York Times | Berkshire Hathaway has disclosed a new investment in the New York Times, reentering a sector it left in 2020. The compan | [Link](https://longbridge.com/zh-CN/news/276173033.md) |
| 04:38 ETAcceleronix e IDEMIA Secure Transactions lanzan el programa de acceso anticipado IFPP | Acceleronix and IDEMIA Secure Transactions have launched the IFPP Early Access Program at MWC26 Barcelona, in collaborat | [Link](https://longbridge.com/zh-CN/news/276429430.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。
